Trials / Completed
CompletedNCT02953743
Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to assess the single- and multiple-dose pharmacokinetic (PK) profile of lenvatinib in Chinese participants with unresectable Hepatocellular Carcinoma (HCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenvatinib | Lenvatinib 4 mg capsules will be administered orally, once daily continuously 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent. |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2017-06-28
- Completion
- 2020-12-28
- First posted
- 2016-11-03
- Last updated
- 2021-04-01
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02953743. Inclusion in this directory is not an endorsement.